Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA
Figure 1
Statewide guidelines for the use of therapeutic drug monitoring (TDM). Diabetes identified by patient self-report or review or chart review by tuberculosis (TB) nurse case managers. *TDM: an estimated peak concentration () for isoniazid and rifampin is collected following directly observed therapy (DOT) and if below the expected range, then a single dose adjustment is made as per guidelines (e.g., rifampin 600 mg daily increased to 900 mg daily or isoniazid 300 mg daily increased to 450 mg daily) [11]. †Slow response defined as persistent or worsening symptoms of TB or lack of decrement in mycobacterial burden in sputum for pulmonary TB patients [11].
